CS
SGMO

Credit Suisse’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Credit Suisse’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,700,000
Closed -$2.22M – 3138
2023
Q3 		$2.22M Hold
3,700,000
– – ﹤0.01% 1767
2023
Q2 		$4.81M Sell
3,700,000
-119,113
-3% -$163K ﹤0.01% 1366
2023
Q1 		$6.72M Buy
3,819,113
+10,967
+0.3% +$31.3K 0.01% 1131
2022
Q4 		$12M Buy
3,808,146
+5,019
+0.1% +$19.5K 0.01% 857
2022
Q3 		$18.6M Buy
3,803,127
+9,827
+0.3% +$50.5K 0.02% 674
2022
Q2 		$15.7M Buy
3,793,300
+3,065
+0.1% +$13.3K 0.02% 767
2022
Q1 		$22M Buy
3,790,235
+202,865
+6% +$1.21M 0.02% 733
2021
Q4 		$26.9M Sell
3,587,370
-1,225
-0% -$10.6K 0.01% 942
2021
Q3 		$32.3M Sell
3,588,595
-8,956
-0.2% -$88.5K 0.02% 839
2021
Q2 		$43.1M Buy
3,597,551
+7,816
+0.2% +$88.5K 0.02% 767
2021
Q1 		$45M Buy
3,589,735
+181,749
+5% +$2.45M 0.02% 755
2020
Q4 		$53.2M Buy
3,407,986
+362,960
+12% +$4.25M 0.03% 680
2020
Q3 		$28.8M Buy
3,045,026
+136,385
+5% +$1.48M 0.02% 839
2020
Q2 		$26.1M Buy
2,908,641
+152,031
+6% +$1.41M 0.02% 816
2020
Q1 		$17.6M Buy
2,756,610
+282,422
+11% +$2.1M 0.02% 912
2019
Q4 		$20.7M Buy
2,474,188
+5,247
+0.2% +$48.2K 0.02% 995
2019
Q3 		$22.3M Buy
2,468,941
+104,529
+4% +$1.17M 0.02% 845
2019
Q2 		$25.5M Buy
2,364,412
+18,068
+0.8% +$192K 0.02% 786
2019
Q1 		$22.4M Buy
2,346,344
+1,201
+0.1% +$12.3K 0.02% 803
2018
Q4 		$26.9M Buy
2,345,143
+160,638
+7% +$2M 0.03% 632
2018
Q3 		$37M Buy
2,184,505
+415,764
+24% +$6.32M 0.03% 549
2018
Q2 		$25.1M Sell
1,768,741
-165,924
-9% -$2.76M 0.02% 716
2018
Q1 		$36.8M Buy
1,934,665
+1,292,860
+201% +$27.6M 0.03% 560
2017
Q4 		$10.5M Buy
641,805
+217,950
+51% +$3.24M 0.01% 1252
2017
Q3 		$6.36M Buy
423,855
+47,167
+13% +$521K 0.01% 1581
2017
Q2 		$3.31M Buy
376,688
+13,410
+4% +$86K ﹤0.01% 1881
2017
Q1 		$1.89M Sell
363,278
-9,490
-3% -$38.1K ﹤0.01% 2381
2016
Q4 		$1.14M Sell
372,768
-26,245
-7% -$95.6K ﹤0.01% 2920
2016
Q3 		$1.85M Buy
399,013
+3,069
+0.8% +$15.6K ﹤0.01% 2440
2016
Q2 		$2.29M Buy
395,944
+30,324
+8% +$193K ﹤0.01% 2233
2016
Q1 		$2.21M Buy
365,620
+54,420
+17% +$327K ﹤0.01% 2126
2015
Q4 		$2.84M Sell
311,200
-3,221
-1% -$24.8K ﹤0.01% 2035
2015
Q3 		$1.77M Sell
314,421
-98,515
-24% -$812K ﹤0.01% 2347
2015
Q2 		$4.58M Buy
412,936
+86,141
+26% +$1.11M ﹤0.01% 1812
2015
Q1 		$5.13M Sell
326,795
-49,223
-13% -$762K 0.01% 1646
2014
Q4 		$5.72M Buy
376,018
+80,361
+27% +$976K 0.01% 1660
2014
Q3 		$3.19M Buy
295,657
+153,296
+108% +$2M ﹤0.01% 2109
2014
Q2 		$2.17M Sell
142,361
-34,162
-19% -$491K ﹤0.01% 2640
2014
Q1 		$3.19M Buy
176,523
+128,265
+266% +$2.47M ﹤0.01% 2140
2013
Q4 		$669K Sell
48,258
-15,330
-24% -$177K ﹤0.01% 3579
2013
Q3 		$667K Buy
63,588
+30,877
+94% +$307K ﹤0.01% 3301
2013
Q2 		$256K Buy
+32,711
New +$285K ﹤0.01% 3725

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Credit Suisse's SGMO Position: Q4 2023 in Review

Credit Suisse sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 3,700,000 shares — an estimated $2.22M sold.

Credit Suisse first reported a position in SGMO in Q2 2013 and held it in 42 quarters. The position peaked at $53.2M in Q4 2020. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Credit Suisse reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 3,700,000 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $2.22M.
  • Credit Suisse first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 42 quarters.
  • Credit Suisse's SANGAMO THERAPEUTICS INC position peaked at $53.2M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.